Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. - Wikidata - awgldk - TriplyDB

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

http://www.wikidata.org/entity/Q37017426

about

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants [Pharmacogenomic Biomarkers for the Prediction of Statin Efficacy and Safety].CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin.Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.The effect of CYP1A2 gene polymorphism on the metabolism of theophylline.

P2860

Q33690357-9DA8E7DA-95C8-485D-BFFD-986EB094C196 Q34163351-77B74F15-F1FE-46D9-B103-1EF6892C0892 Q35158967-84FC2670-2791-4B7A-97BE-67F3EDE6EC56 Q36927210-85C898C5-F5A5-4EDF-AB86-B22914547AEF Q37613067-8C93BF2A-1302-4C92-B4E8-9F0DE9163F09 Q37646573-42CF7D9B-8B37-45E3-8DE4-66E0815E9557 Q37720189-9D3C7FFB-D433-4C8A-A950-01FF25E54BAE Q38726643-7A0596CB-95D2-404B-BC99-1548871ED72D Q49637368-8F8EDBC4-145A-4ED1-B0DD-035D7D8CB905

P2860

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

http://www.wikidata.org/entity/Q37017426

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of cytochrome P450 3A5 ...... teraction with clarithromycin.

@en

Effect of cytochrome P450 3A5 ...... teraction with clarithromycin.

@nl

type

label

Effect of cytochrome P450 3A5 ...... teraction with clarithromycin.

@en

Effect of cytochrome P450 3A5 ...... teraction with clarithromycin.

@nl

prefLabel

Effect of cytochrome P450 3A5 ...... teraction with clarithromycin.

@en

Effect of cytochrome P450 3A5 ...... teraction with clarithromycin.

@nl

P1433

Q37017426-9E1081E2-9774-44D2-9C33-D60058A220C3

P1476

Q37017426-50E8E63F-22AD-46EC-9718-701F486E603D

P2093

Q37017426-400C64EA-9769-4C00-8A91-46D15EBCB72E

Q37017426-91553779-BDDF-47DB-95B6-BE7741C08D91

Q37017426-B7FE9E9D-2944-4CD0-8C45-641ECF50139E

Q37017426-D571562A-386C-48F9-845B-17042837235E

P2860

Q37017426-092C409D-8F49-41C6-BDF6-6CE10EA331DB

Q37017426-117DE846-ED50-45C0-AF06-212EC98E9F03

Q37017426-256136A4-A59D-4B2E-B15C-B41CA728B180

Q37017426-2A47D69A-3999-49ED-B922-4AE17A5D490F

Q37017426-2ED48A3B-E4F9-43C8-9BBF-6761F82A8EC0

Q37017426-50EBA3CA-E703-47D3-A0DF-0E3ED922F920

Q37017426-56242374-0A37-4C30-A3DD-8305C0086345

Q37017426-5ABCF2AA-011D-4173-9D21-AE543793477B

Q37017426-5F80D5F5-1857-4079-8171-E7AC1E7704AC

Q37017426-64FE9DC2-AEF9-49E1-9361-9C3B63CC28D3

P304

Q37017426-5C0DA10B-9F37-41F8-ABB9-A005CE620FC5

P31

Q37017426-AE0D3E4C-583A-4139-AD17-A0CDDAA028FD

P356

Q37017426-A5AFD8F3-182C-477D-ADAB-62F143418221

P407

Q37017426-E941ADED-C1A2-436B-98F5-FB708C959B0D

P433

Q37017426-6354B99B-3EC5-4E51-A499-CD9C98DBD6D1

P478

Q37017426-837AC2A0-1140-47AA-9D0B-2DB001340A42

P50

Q37017426-856DB313-F698-49A7-923F-832933C87DD9

Q37017426-DED5FB2A-A5E9-476C-9B81-46FE2FE9A822

P577

Q37017426-65319B14-7CC5-48E3-B9DA-16EC95E42C24

P698

Q37017426-2E4362E4-3E9C-4D44-B3F1-F869E11B5F47

P932

Q37017426-8F797952-BD20-4AE8-ACC0-DB1A8B756938

P356

P1433

Pharmacotherapy

P1476

Effect of cytochrome P450 3A5 ...... nteraction with clarithromycin

@en

P2093

Daniel F Pauly

http://www.w3.org/2001/XMLSchema#string

Jaekyu Shin

http://www.w3.org/2001/XMLSchema#string

Julie A Johnson

http://www.w3.org/2001/XMLSchema#string

Michael A Pacanowski

http://www.w3.org/2001/XMLSchema#string

P2860

Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.

Statin-associated myopathy.

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.

Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.

Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.

Heterotropic cooperativity in oxidation mediated by cytochrome p450.

Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry.

Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.

Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.

P304

942-950

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.31.10.942

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Reginald F. Frye

Taimour Langaee

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21950641

http://www.w3.org/2001/XMLSchema#string

P932

3712822

http://www.w3.org/2001/XMLSchema#string